Trial Profile

A Study to Compare the Consequences of Failures to Integrase Inhibitor (INI)‐Based or Protease Inhibitor (PI)‐Based Triple Therapies (TT) Versus Two Drug Combinations (2DC) in Patients with No Previous Virological Failures in their Therapeutic Histories

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Jan 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atazanavir/ritonavir (Primary) ; Cobicistat/elvitegravir (Primary) ; Darunavir/ritonavir (Primary) ; Dolutegravir (Primary) ; Lamivudine (Primary) ; Peptide hydrolase inhibitors (Primary) ; Raltegravir (Primary) ; Rilpivirine (Primary)
Indications HIV infections
Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com